

Patent Application
Attorney Docket No.9517H

By _____
I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 28 day of October 2003.

By _____

T. Mycroft
(Signature of person mailing)

Tracy Mycroft

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David B. MacLean et al. :

APPLICATION NO.: 10/615,282 : Examiner: To be Assigned

FILING DATE: 7/7/2003 : Group Art Unit: 1614

TITLE: Use of Estrogen Antagonists and Estrogen
Agonists in Inhibiting Pathological Conditions :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Date: 10/28/2003

Respectfully submitted,

Todd M. Crissey
Todd M. Crissey
Attorney for Applicant(s)
Reg. No. 37,807


Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>							ATTY. DOCKET NO. PC9517H			SERIAL NO. 10/615,282			
							APPLICANT David B. MacLean, et al.						
							FILING DATE 7/7/2003			GROUP 1614			
U.S. PATENT DOCUMENTS													
	US	3	2	3	4	0	9	0	2/8/66	Charles F. Huebner	167	58	
	US	3	2	7	4	2	1	3	9/20/66	Daniel Lednicer	260	326.5	
	US	3	2	7	7	1	0	6	10/4/66	William L. Bencze	260	295	
	US	3	2	9	3	2	6	3	12/20/66	Daniel Lednicer	260	326.5	
	US	3	3	2	0	2	7	1	5/16/67	Daniel Lednicer	260	307	
	US	3	3	9	6	1	6	9	8/6/68	Daniel Lednicer	260	294.7	
	US	3	4	8	3	2	9	3	12/9/69	Gordon W. Duncan	424	274	
	US	3	5	6	7	7	3	7	3/2/71	Daniel Lednicer	37	00	
	US	3	8	6	2	2	3	2	1/21/75	Daniel Lednicer	260	570.7	
	US	4	1	3	3	8	1	4	1/9/79	C. David Jones	260	326.55	
	US	4	3	5	8	5	9	3	11/9/82	Jones, et al.	546	202	
	US	4	3	8	0	6	3	5	4/19/83	Mary K. Peters	546	202	
	US	4	4	1	8	0	6	8	11/29/83	Charles D. Jones	424	267	
	US	4	8	5	9	5	8	5	8/22/89	Sonnenschein et al.	435	29	
	US	5	0	4	7	4	3	1	9/10/91	Schickaneder et al.	514	648	
	US	5	2	5	4	5	9	4	10/19/93	Niikura et al.	514	648	
	US	5	3	6	4	7	9	1	11/15/94	Vegeto et al.	435	320.1	
	US	5	3	8	4	3	3	2	1/24/95	Steven A. Fontana	514	648	
	US	5	3	8	9	6	7	0	2/14/95	Steven A. Fontana	514	443	
	US	5	3	9	1	5	5	7	2/21/95	Cullinan et al.	514	324	
	US	5	3	9	3	7	6	3	2/28/95	Black et al.	514	333	
	US	5	4	1	8	2	5	2	5/23/95	Daniel C. Williams	514	443	
	US	5	4	3	4	1	6	6	7/18/95	A.L. Glasebrook	514	317	
	US	5	4	3	9	9	2	3	8/8/95	George J. Cullinan	514	324	
	US	5	4	3	9	9	3	1	8/8/95	James J. Sales	514	443	
	US	5	4	4	1	9	6	6	8/15/95	Jeffrey A. Dodge	514	324	
	US	5	4	4	1	9	8	6	8/15/95	David D. Thompson	514	648	
	US	5	4	4	6	0	5	3	8/29/95	Patrick Keohane	514	324	



INFORMATION DISCLOSURE CITIGATION <i>(Use several sheets if necessary)</i>							ATTY. DOCKET NO. PC9517H			SERIAL NO. 10/615,282					
							APPLICANT David B. MacLean, et al.			FILING DATE 7/7/2003			GROUP 1614		
							US	5	4	4	7	9	4	1	9/5/95
US	5	4	5	1	5	8	9	9/19/95	Jeffrey A. Dodge	514	324				
US	5	4	5	1	5	9	0	9/19/95	Jeffrey A. Dodge	514	324				
US	5	4	5	5	2	7	5	10/3/95	Steven A. Fontana	514	648				
US	5	4	5	7	1	1	3	10/10/95	Cullinan et al.	514	319				
US	5	4	5	7	1	1	6	10/10/95	Black et al.	514	324				
US	5	4	5	7	1	1	7	10/10/95	Black et al.	514	337				
US	5	4	6	1	0	6	4	10/24/95	George J. Cullinan	514	324				
US	5	4	6	1	0	6	5	10/24/95	Black et al.	514	324				
US	5	4	6	2	9	3	7	10/31/95	Cullinan et al.	514	212				
US	5	4	6	2	9	4	9	10/31/95	Jones et al.	514	324				
US	5	4	6	2	9	5	0	10/31/95	Steven A. Fontana	514	324				
US	5	4	5	4	8	4	5	11/7/95	Black et al.	514	326				
US	5	4	7	0	8	5	4	11/28/95	Angerer, et al.	514	233.5				
US	5	4	7	0	8	8	3	11/28/95	Brent V. Stromberg	514	648				
US	5	4	8	2	9	4	9	1/9/96	Black, et al.	514	324				
US	5	4	7	2	9	6	2	12/5/95	Koizumi, et al.	514	233.5				
US	5	4	8	4	7	9	8	1/16/96	Bryant, et al.	514	324				
US	5	5	1	0	3	5	7	4/23/96	Alan Palkowitz	514	324				
US	5	5	3	2	3	8	2	7/2/96	Carlson, et al.	549	57				
US	5	5	5	0	1	6	4	8/27/96	Steven A. Fontana	514	648				
US	5	5	5	2	4	1	2	9/3/96	Cameron, et al	514	317				
US	5	5	6	7	8	2	8	10/22/96	Jeffrey A. Dodge	549	51				
US	5	8	7	7	2	1	6	3/2/99	Place et al.	514	573				
US	5	8	8	9	0	4	2	3/30/99	MacLean et al.	514	127				
US	6	1	0	7	3	3	1	8/22/00	MacLean et al.	514	428				
US	6	1	5	3	6	2	2	11/28/00	Cameron et al.	514	307				
US	6	2	0	4	2	8	6	3/20/01	Cameron et al.	514	428				
US	6	2	4	5	8	1	9	6/12/01	Halonen et al.	514	721				



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)								ATTY. DOCKET NO. PC9517H			SERIAL NO. 10/615,282		
								APPLICANT David B. MacLean, et al.					
								FILING DATE 7/7/2003			GROUP 1614		

	US	6	4	0	3	6	1	1	6/11/02	MacLean et al.	514	315	
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
	EP	0	3	0	9	4	7	3	4/5/89	European	A61L	33/00			
	EP	0	6	0	5	1	9	3	7/6/94	European	A61K	31/40			
	EP	0	6	1	7	0	3	0	9/28/94	European	Co7D	333/56			
	EP	0	6	3	5	2	6	4	1/25/95	European	A61K	31/38			
	EP	0	6	5	2	0	0	4	5/10/95	European	A61K	31/4465			
	EP	0	6	5	9	4	1	1	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	1	3	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	1	4	6/28/95	European	A61K	34/445			
	EP	0	6	5	9	4	1	5	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	1	8	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	1	9	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	2	5	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	2	7	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	2	8	6/28/95	European	A61K	31/445			
	EP	0	6	5	9	4	2	9	6/28/95	European	A61K	31/445			
	EP	0	6	6	4	1	2	1	7/26/95	European	A61K	31/4535			
	EP	0	6	6	4	1	2	3	7/26/95	European	A61K	31/445			
	EP	0	6	6	4	1	2	5	7/26/95	European	A61K	31/445			
	EP	0	6	6	4	1	2	6	7/26/95	European	A61K	31/445			
	EP	0	7	9	2	6	4	0	09/03/97	European	A61K	31/135			
/	EP	0	7	9	2	6	4	1	9/3/97	European	A61K	31/40			
	WO	9	3	0	7	1	4	9	4/15/93	International	C07D	487/04			
	WO	9	5	1	0	5	1	3	4/20/95	International	C07D	333/56			



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						ATTY. DOCKET NO. PC9517H				SERIAL NO.10/615,282				
						APPLICANT David B. MacLean, et al.								
						FILING DATE 7/7/2003				GROUP 1614				
	WO	9	6	2	1	6	5	6	7/18/96	International	C07D	295/08		
	WO	9	7	2	9	7	3	5	8/21/97	International	A61K	7/42		
	WO	9	7	4	3	2	7	2	11/20/97	International	C07D	307/79		
	WO	9	8	3	3	4	9	9	8/6/98	International	A61K	31/40		
	WO	9	8	4	9	1	6	6	11/5/98	International	C07D	487/04		
	WO	9	9	0	0	0	1	9	1/7/99	International	A01N	43/40		
	WO	9	9	2	1	5	6	2	5/6/99	International	A61K	31/557		
	WO	0	0	7	6	5	2	2	12/21/00	International	A61K	31/56		
OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)														
			W.L. Bencze, et al., <u>J. Med. Chem.</u> , "Synthetic Estrogens, Implantation Inhibitors, and Hypocholesterolemic Agents. I. Tetrahydronaphthalene Series", Volume 10, pages 138-144 (1967)											
			W.L. Bencze, et al. <u>J. Med. Chem.</u> , "Selective Adrenal Cortical and Gonadal Inhibitors", Volume 5, pages 1298-1306 (1962)											
			M. Gordaliza, et al., <u>Bioorganic and Medicinal Chemistry Letters</u> , "Selective Cytotoxic Cyclolignans", Volume 5, No. 21, pages 2465-2468 (1995)											
			C.D. Jones, et al., <u>J. Med. Chem.</u> , "Antiestrogens. 2. Structure-Activity Studies in a Series of 3-aryl-2-arylbenzo[b]thiopene Derivatives Leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride (LY 156758), a Remarkably Effective Estrogen Antagonist With Only Minimal Intrinsic Estrogenicity", Volume 27, pages 1057-1066 (1984)											
			D. Lednicer, et al., <u>J. Med. Chem.</u> , "Mammalian Antifertility Agents. IV. Basic 3,4-dihydronaphthalenes and 1,2,3,4-Tetrahydro-1-naphthols ^{1,2} ", Volume 10, pages 78-84 (1967)											
			D. Lednicer, et al., <u>J. Med. Chem.</u> , "Mammalian Antifertility Agents. VI. A Novel Sequence for the Preparation of 1,2-Disubstituted 3,4-Dihydronaphthalenes", Volume 12 pages 881-884 (1969)											
			R.L. Metcalf, et al., <u>Journal of Agricultural Food Chemistry</u> , "Mode of Action of Carbamate Synergists", Volume 14 No. 6, pages 555-562 (1966)											
			M. P. Wentland, et al., <u>J. Med. Chem.</u> , "Synthesis and Antidepressant Properties of Novel 2-Substituted 4,5-Dihydro-1H-imidazole Derivatives", Volume 30, pages 1482-1489 (1987)											
			K. Nagarajan, et al. <u>Indian Journal of Chemistry</u> , "Antiimplantation Agents: Part II ^a – 1,2-Diaryl-1,2,3,4-tetrahydroisoquinolines ^{b,c} ", Volume 24B, pages 83-97 (1985)											
			M. T. Tzukerman, et al., <u>Molecular Endocrinology</u> , "Human Estrogen Receptor Transactivational Capacity Is Determined by both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions", Volume 8 No. 1, pages 21-30 (1994)											
			C. Tilford, et al., <u>Journal of American Chemical Society</u> , "Aminoesters of 1-Substituted Alicyclic Carboxylic Acids", Volume 71 pages 1705-1709 (1949)											
			<i>Drug Design</i> , Volume VIII, New York: Academic Press, New York, New York, 1979, pages 182-191											
			Gayland P. Spencer, <u>Journal of Natural Products</u> , "The Effects of a Terpene Aldehyde-Ester from Eryngium Paniculatum and Analogs on Velvetleaf Germination", Volume 49, No. 5, pages 924-926 (1986)											
			Robert C. Jones, <u>Acta Endocrinologica</u> , "The Effect of A Luteinizing Hormone-Releasing Hormone Antagonist On Experimental											



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC9517H	SERIAL NO. 10/615,282
			APPLICANT David B. MacLean, et al.	
			FILING DATE 7/7/2003	GROUP 1614
			Endometriosis in the Rat", Volume 114 pages 379-382 (1987)	
			Osteoporosis Conference, SCRIP No. 1812/13, April 16 th /20 th pages 29-30 (1993)	
			Roland Loser et al., Eur. J. Cancer Clin. Oncol., "In Vivo and In Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Volume 21, No. 8, pages 985-990 (1985)	
			Urs Eppenberger et al., Am. J. Clin. Oncol., "Pharmacologic and Biologic Properties of Droloxifene, A New Antiestrogen", Volume 14, Suppl. 2, S5-S14 (1991)	
EXAMINER			DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE